Mutation of Tp53 contributes to the malignant phenotype of abelson virus-transformed lymphoid cells

Journal of Virology

Volumn 71, Issue 11, 1997, Pages 8149-8156

  Thome, Kelly C ^a,b   Radfar, Arash ^a   Rosenberg, Naomi ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; GENE MUTATION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION;

EID: 0030849536     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.11.8149-8156.1997     Document Type: Article

References (64)

1. Aguilar, F., S. P. Hussain, and P. Cerutti. 1993. Aflatoxin B1 induces the transversion of G to T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA 90:8586-8590.
2. Ahuja, H., M. Bar-Eli, S. H. Advani, S. Benchimol, and M. J. Cline. 1989. Alterations in the p53 gene and the clonal evolution irf the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. USA 86:6783-6787.
3. Aloni-Grinsten, R., I. Zan-Bar, I. Alboum, N. Goldfinger, and V. Roller. 1993. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 8:3297-3305.
4. Baxter, E. W., K. Blyth, L. A. Donehower, E. R. Cameron, D. E. Onions, and J. C. Neil. 1996. Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? J. Virol. 70:2095-2100.
5. Ben-David, Y., and A. Bernstein. 1991. Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 66:831-834.
6. Bergeron, D., J. Houde, L. Polquin, B. Barbeau, and E. Rassart. 1993. Analysis of proviruses integrated in the Fli-1 and Evi-1 regions in Cas-Br-E MuLV-induced non-T. non B-cell leukemias. Virology 191:661-669.
7. Berstine, E. G., M. L. Hooper, S. Grandchamp, and B. Ephrussi. 1973. Alkaline phosphatase activity in mouse teratoma. Proc. Natl. Acad. Sci. USA 70:3899-3903.
8. Bhatia, K. G., M. I. Gutierrez, K. Huppi, D. Siwarski, and I. T. Magrath. 1992. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 52:4273-4276.
9. Cawthon, R. M., L. B. Anderson, A. M. Buchberg, G. Xu, P. O'Connell, D. Viskochil, R. B. Weiss, M. R. Wallace, D. A. Marchuk, M. Culver, J. Stevens, N. A. Jenkins, N. G. Copeland, F. S. Collins, and R. White. 1991. cDNA sequences and genomic structure of EVI-2B, a gene lying within an intron of the neurofibromatosis type 1 gene. Genomics 9:446-460.
10. Chen, Y. Y., and N. Rosenberg. 1992. Lymphoid cells transformed by Abelson virus require the v-abl protein tyrosine kinase only during early G1. Proc. Natl. Acad. Sci. USA 89:6683-6687.
11. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
12. Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
13. Cox, D. R. 1972. Regression models and life tables (with discussion). J. R. Stat. Soc. 74:187-220.
14. Datto, M. B., Y. Li, J. F. Panus, D. J. Howe, Y. Xiong, and X.-F. Wang. 1995. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 92:5545-5549.
15. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
16. Engelman, A., and N. Rosenberg. 1990. Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J. Virol. 64:4242-4251.
17. Farthing, A. J., and K. H. Vousden. 1994. Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol. 2:170-174.
18. Finlay, C. A., P. W. Hinds, T.-H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. 1988. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8:531-539.
19. Goff, S. P., O. N. Witte, E. Gilboa, N. Rosenberg, and D. Baltimore. 1981. Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells. J. Virol. 38:460-468.
20. Green, P. L., D. A. Kaehler, L. M. Bennett, and R. Risser. 1989. Multiple steps are required for the induction of tumors by Abelson murine leukemia virus. J. Virol. 63:1989-1994.
21. Green, P. L., D. A. Kaehler, and R. Risser. 1987. Clonal dominance and progression in Abelson murine leukemia virus lymphomagenesis. J. Virol. 61:2192-2197.
22. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to the cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
23. Gu, Y., C. W. Truck, and D. O. Morgan. 1993. Inhibition of cdk2 activity in vivo by an associated 20k regulatory subunit. Nature 366:707-710.
24. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1-cyclin-dependent kinases. Cell 75:805-816.
25. Harvey, D. M., and A. J. Levine. 1991. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5:2375-2385.
26. Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorensen, R. Montesano, and C. C. Harris. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:3551-3555.
27. Holmes, K. L., J. H. Pierce, W. F. Davidson, and H. C. Morse III. 1986. Murine hematopoietic cells with pre-B or pre-B/myeloid characteristics are generated by in vitro transformation with retroviruses containing fes, ras, abl, and src oncogenes. J. Exp. Med. 164:443-457.
28. Hunter, T. 1997. Oncoprotein networks. Cell 88:333-346.
29. Imamura, J., I. Miyoshi, and H. P. Koeffler. 1994. p53 in hematologic malignancies. Blood 84:2412-2421.
30. Kasten, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
31. Kinzler, K. W., and B. Vogelstein. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-170.
32. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
33. Kurzrock, R., J. U. Gutterman, and M. Talpaz. 1988. The molecular genetics of Philadelphia chromosome positive leukemias. N. Engl. J. Med. 319:990-998.
34. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
35. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849.
36. Ludlow, J. W. 1993. Interaction between SV40 large tumor antigen and the growth suppressor proteins pRB and p53. FASEB J. 7:866-871.
37. Manfredi, J. J., and C. Prives. 1994. The transforming activity of simian virus 40 large tumor antigen. Biochim. Biophys. Acta 1198:65-83.
38. Moran, E. 1993. Interaction of adenoviral proteins with pRB and p53. FASEB J. 7:880-885.
39. Parmar, K., and N. Rosenberg. 1996. Ras complements lhe carhoxyl terminus of v-Abl protein in lymphoid transformation. J. Virol. 70:1009-1015.
40. Prokocimer, M., and V. Rotter. 1994. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84:2391-2411.
41. Radfar, A., J. Mosleckj, and N. Rosenberg. Unpublished data.
42. Rolink, A., U. Grawunder, D. Haasner, A. Strasser, and F. Melchers. 1993. Immature surface Ig+ B cells can continue to rearrange kappa and lambda L chain gene loci. J. Exp. Med. 178:1263-1270.
43. Rosenberg, N. 1991. abl oncogenes. Semin. Virol. 2:365-374.
44. Rosenberg, N. 1994. abl-mediated transformation, immunoglobulin gene rearrangements and arrest of B lymphocyte differentiation. Semin. Cancer Biol. 5:95-102.
45. Rosenberg, N., and D. Baltimore. 1976. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J. Exp. Med. 143:1453-1463.
46. Sawyers, C. L. 1992. The bcr-abl gene in chronic myelogenous leukemia. Cancer Surv. 15:37-51.
47. Sherr, C. J. 1996. Cancer cell cycles. Science. 274:1672-1677.
48. Soussi, T., C. Caron de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952.
49. Srinivasan, R., J. A. Roth, and S. A. Maxwell. 1993. Sequence-specific interaction of a conformational domain of p53 with DNA. Cancer Res. 53: 5361-5364.
50. Stephen, C. W., and D. P. Lane. 1992. Mutant conformation of p53: precise epitope mapping using a filamentous phage library. J. Mol. Biol. 225:577-583.
51. Sun, X. M., R. T. Snowden, D. N. Skilleter, D. Dinsdale, M. G. Ormerod, and G. M. Cohne. 1992. A flow-cytometric method for the separation and quantitation of normal and apoptotic thymocytes. Anal. Biochem. 204:351-356.
52. Thome, K., and N. Rosenberg. Unpublished data.
53. Tommasino, M., and L. Crawford. 1995. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays 17:303-310.
54. Ulrich, E., G. Boehmelt, A. Bird, and H. Beug. 1992. Immortalization of conditionally transformed chicken cells: loss of normal p53 expression is an early step that is independent of cell transformation. Genes Dev. 86:876-887.
55. Viskochil, D., A. M. Buchberg, G. Xu, R. M. Cawthon, J. Stevens, R. K. Wolff, M. Culver, J. C. Carey, N. G. Copeland, N. Jenkins, R. White, and P. O'Connell. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192.
56. White, E. 1995. Regulation of p53-dependent apoptosis by E1A and E1B. Curr. Top. Microbiol. Immunol. 199:34-58.
57. Whitlock, C. A., and O. N. Witte. 1981. Abelson virus-infected cells exhibit restricted in vitro growth and low oncogenic potential. J. Virol. 40:577-584.
58. Whitlock, C. A., S. F. Ziegler, and O. N. Witte. 1983. Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes. Mol. Cell. Biol. 3:596-604.
59. Witte, O. N., N. Rosenberg, and D. Baltimore. 1979. Preparation of syngeneic tumor regressor serum reactive with the unique determinants of the Abelson murine leukemia virus-encoded p120 protein at the cell surface. J. Virol. 31:776-784.
60. Wolf, D., S. Admon, M. Oren, and V. Rotter. 1984. Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. Mol. Cell. Biol. 4:552-558.
61. Wolf, D., N. Harris, and V. Rotter. 1984. Reconstitution of p53 expression in a nonproducer Ab-MLV-transformed cell line by transfection of a functional p53 gene. Cell 38:119-126.
62. Wolf, D., and V. Rotter. 1984. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Mol. Cell. Biol. 4:1402-1410.
63. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:707-710.
64. Yonish-Rouach, E., D. Resnitzky, J. Lotm, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347.